Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.34 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.33 |
| ▸ | RORC | P51449 | 6/20 | 0.32 |
| ▸ | APP | P05067 | 2/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | RORA | P35398 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18559860 | 0.95 | S1PR1 (0.35) | S1PR1S1PR3RARBGRM2AKR1C3 | |
| SCHEMBL18314925 | 0.94 | RARB (0.37) | S1PR1S1PR3RARBGRM2RORC | |
| SCHEMBL18314829 | 0.91 | GRM2 (0.34) | S1PR1S1PR3RARBGRM2AKR1C3 | |
| SCHEMBL18315082 | 0.91 | S1PR1 (0.33) | S1PR1S1PR3RARBGRM2AKR1C3 | |
| SCHEMBL18314922 | 0.91 | RARB (0.37) | S1PR1S1PR3RARBGRM2AKR1C3 | |
| SCHEMBL18314999 | 0.90 | GRM2 (0.35) | S1PR1S1PR3RARBGRM2AKR1C3 | |
| SCHEMBL18314836 | 0.89 | GRM2 (0.34) | S1PR1S1PR3RARBGRM2AKR1C3 | |
| SCHEMBL17050131 | 0.88 | RARB (0.39) | S1PR1S1PR3RARBGRM2PDK2 | |
| SCHEMBL18314811 | 0.87 | RARB (0.38) | S1PR1S1PR3RARBGRM2AKR1C3 | |
| SCHEMBL18559863 | 0.87 | S1PR1 (0.35) | S1PR1S1PR3RARBGRM2AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160362605-A1 | LIQUID CRYSTAL COMPOUND HAVING 1,1,3,3-TETRAFLUOROALLYLOXY GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362605-A1 | LIQUID CRYSTAL COMPOUND HAVING 1,1,3,3-TETRAFLUOROALLYLOXY GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | TCOF1, PIEZO1, RCC1 | S1PR1 3198/4885S1PR3 4003/4885RARB 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.